Table 2 Maternal and fetal/neonatal outcomes

 Treatment duration (days)

 Gestational age at delivery (weeks + days)

 Pregnancy prolongation after randomisation (days)

 Abdominal circumference at ultrasound closest to 2 weeks after randomisation (mm)

Mode of delivery

 Caesarean section on fetal indication (%)

 Caesarean section on maternal indication (%)

 Induced vaginal delivery on fetal indication (%)

 Induced vaginal delivery on maternal indication (%)

 Spontaneous vaginal delivery (%)

 Induction of labour after intra-uterine death (%)

Pregnancy induced hypertension (%)

Preeclampsia (%)

HELLP syndrome (%)

 One antihypertensive

 Two antihypertensives

 Three or more antihypertensives

Maternal need for magnesium sulphate for hypertension (%)

Neonate born between 48 h and 14 days after antenatal corticosteroids course (complete course) (%)

Neonate born between 0 and 48 h after antenatal corticosteroids course (incomplete course) (%)

Neonate born during maternal administration of intravenous magnesium sulphate (%)

 Intra-uterine death (%)

 Neonatal death (%)

 Survival at hospital discharge (%)

 Survival with relevant morbidity at hospital discharge (%)

 Survival without relevant morbidity at hospital discharge (%)

 Birth weight of neonates with intra-uterine death (grammes)

 Birth weight of neonates with live birth (grammes)

 Postmenstrual age at first discharge home (weeks + days)

 IVH grade III or IV (%)

 PVL grade II or more (%)

 Moderate or severe BPD (%)

 No BPD (%)

 ROP treated by laser or surgery (%)

 One or more culture-proven episode of infection or clinical episode of infection with antibiotic treatment necessary ≥ 5 days (%)

 NEC grade II or more (%)